Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Clinical trial NCT04460430 · TERMINATED
Trial details
- NCT number
- NCT04460430
- Sponsor
- SOLTI Breast Cancer Research Group
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-23
- Primary completion
- 2021-11-29
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.